Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: Factors impacting levels of and associations between serum troughs, efficacy, and toxicity

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2371-2377

  Mitsani, Dimitra ^a   Nguyen, M Hong ^a   Shields, Ryan K ^a   Toyoda, Yoshiya ^a   Kwak, Eun J ^a   Silveira, Fernanda P ^a   Pilewski, Joseph M ^a   Crespo, Maria M ^a   Bermudez, Christian ^a   Bhama, Jay K ^a   Clancy, Cornelius J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VA Pittsburgh Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; VORICONAZOLE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CYSTIC FIBROSIS; DELIRIUM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FUNGAL COLONIZATION; FUNGUS CULTURE; HUMAN; HYPERTRANSAMINASEMIA; LIVER TOXICITY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUROTOXICITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SIDE EFFECT; TRACHEOBRONCHITIS; VISUAL DISORDER;

ADULT; AGED; ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTIC FIBROSIS; DRUG MONITORING; FEMALE; FUNGI; HUMANS; LIVER; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES;

EID: 84860133248     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05219-11     Document Type: Article

References (41)

1. Amigues I, et al. 2010. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 16:46-52.
2. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34.
3. Appignani BA, et al. 1996. Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. AJR Am. J. Roentgenol. 166:683-688. (Pubitemid 26065184)
4. Berge M, et al. 2009. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl. Infect. Dis. 11:211-219.
5. Boyd AE, et al. 2004. Adverse reactions to voriconazole. Clin. Infect. Dis. 39:1241-1244. (Pubitemid 40169325)
6. Bruggemann RJ, et al. 2008. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. Ther. Drug Monit. 30:643-646.
7. Bruggemann RJ, et al. 2008. Therapeutic drug monitoring of voriconazole. Ther. Drug Monit. 30:403-411.
8. Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A. 2011. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr. Infect. Dis. J. 30:533-534.
9. Chamilos G, et al. 2007. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin. Ther. 29:1980-1986. (Pubitemid 350212807)
10. Denning DW, et al. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571. (Pubitemid 34165316)
11. De Pauw B, et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
12. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. December 2004. Division of AIDS table for grading the severity of adult and pediatric adverse events. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. www3.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/PDF/ DAIDSAEGradingTable.pdf.
13. Eggermont E, De Boeck K. 1991. Small-intestinal abnormalities in cystic fibrosis patients. Eur. J. Pediatr. 150:824-828.
14. Freifeld A, et al. 2007. Relationship of blood level and susceptibility in voriconazole treatment of histoplasmosis. Antimicrob. Agents Chemother. 51:2656-2657. (Pubitemid 47047362)
15. Han K, Bies R, Johnson H, Capitano B, Venkataramanan R. 2011. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. Clin. Pharmacokinet. 50:201-214.
16. Han K, et al. 2010. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob. Agents Chemother. 54:4424-4431.
17. Howard A, Hoffman J, Sheth A. 2008. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann. Pharmacother. 42:1859-1864.
18. Husain S, et al. 2006. Voriconazole prophylaxis in lung transplant recipients. Am. J. Transplant. 6:3008-3016.
19. Husain S, et al. 2011. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J. Heart Lung Transplant. 30:361-374.
20. Imhof A, Schaer DJ, Schanz U, Schwarz U. 2006. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med. Wkly. 136:739-742. (Pubitemid 46032197)
21. Johnson HJ, et al. 2010. Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob. Agents Chemother. 54:852-859.
22. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. 2002. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42:395-402. (Pubitemid 34259773)
23. Levine SM. 2004. A survey of clinical practice of lung transplantation in North America. Chest 125:1224-1238. (Pubitemid 38501333)
24. Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND. 2003. Safety of voriconazole and dose individualization. Clin. Infect. Dis. 36:1087-1088.
25. Miyakis S, van Hal SJ, Ray J, Marriott D. 2010. Voriconazole concentrations and outcome of invasive fungal infections. Clin. Microbiol. Infect. 16:927-933.
26. Neoh CF, et al. 2011. Antifungal prophylaxis in lung transplantation: a world-wide survey. Am. J. Transplant. 11:361-366.
27. Nicolls MR, Zamora MR. 2010. Bronchial blood supply after lung transplantation without bronchial artery revascularization. Curr. Opin. Organ Transplant. 15:563-567.
28. Pai MP, Lodisa TP. 2010. Pharmacokinetics (PK) of voriconazole in obese adults. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr A1-044.
29. Pascual A, et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. (Pubitemid 351269158)
30. Pearson FG, Goldberg M, Stone RM, Colapinto RF. 1970. Bronchial arterial circulation restored after reimplantation of canine lung. Can. J. Surg. 13:243-250.
31. Siegelman SS, Hagstrom JW, Koerner SK, Veith FJ. 1977. Restoration of bronchial artery circulation after canine lung allotransplantation. J. Thorac. Cardiovasc. Surg. 73:792-795. (Pubitemid 8088444)
32. Smith J, Andes D. 2008. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther. Drug Monit. 30:167-172. (Pubitemid 351521643)
33. Smith J, et al. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
34. Sole A, Morant P, Salavert M, Peman J, Morales P. 2005. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin. Microbiol. Infect. 11:359-365. (Pubitemid 40575818)
35. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243. (Pubitemid 43146453)
36. Theuretzbacher U, Ihle F, Derendorf H. 2006. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663. (Pubitemid 43990568)
37. Trifilio S, et al. 2005. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 35:509-513. (Pubitemid 40403355)
38. Trifilio S, et al. 2007. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109:1532-1535.
39. Trifilio S, et al. 2007. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 40:451-456. (Pubitemid 47288224)
40. Trifilio SM, et al. 2009. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob. Agents Chemother. 53:1793-1796.
41. Vadnerkar A, et al. 2011. Age-specific complications among lung transplant recipients 60 years and older. J. Heart Lung Transplant 30:273-281.